Developing game changing treatments and cell therapies for severe diseases

We develop and commercialize innovative treatments for patients with severe and life-threatening conditions. Our products have the potential to improve outcomes in the treatment of neurological and opthalmic disease and for ground-breaking regenerative cell therapies. They give hope for patients lacking satisfactory alternatives.


“We are very excited about the clinical potential for ILB, which may prove to be a game changing treatment for many devastating diseases.”

Professor Ann Logan,
Scientific Director, Neuregenix Ltd.


March 13, 2020
TIKOMED secures 5 M € funding for the clinical development of ILB™ and IBSOLVMIR®
Viken – 13th March 2020 – TIKOMED, a Swedish privately-held biopharmaceutical company today announced that it has successfully completed a €5 million round of financing from current investors. The capital will primarily be used to support the ongoing clinical development program for ILB™ and IBSOLVMIR®, advancing the company’s position within the treatment of acute and…
Read More
March 9, 2020
Locust Walk appointed Strategic and Business Development Advisor for the licensing process of ILB™
Viken – 9th March 2019 – TIKOMED, a Swedish privately held biopharmaceutical company today announced the appointment of Locust Walk (LW) as strategic advisor and business development representative for the licensing process of ILB™.   “We are very pleased to secure this new collaboration as we have already worked closely with Locust Walk over the…
Read More
June 14, 2019
Information regarding our ongoing Amyotrophic Lateral Sclerosis (ALS) study at Sahlgrenska University Hospital
Since we get several questions about our ongoing Amyotrophic Lateral Sclerosis (ALS) study at Sahlgrenska University Hospital, we want to provide the following information on behalf of the company: 1. The study is closed 2. We plan to report the study’s outcome as soon as the analysis of the study is completed in 2020. 3.…
Read More
March 4, 2019
TFS International AB (TFS) appointed CRO representative for TIKOMED’s phase 2 study in clinical islet transplantation
Viken – 4th March 2019 – TIKOMED, a Swedish privately held biopharmaceutical company today announced the appointment of TFS to perform CRO services for TIKOMED’s Phase 2 study in clinical islet transplantation. The study is planned to be performed as an international multi-center study. IBsolvMIR is TIKOMED’s immune modulating drug candidate currently in Phase 2…
Read More


June 3, 2019
BIO International
TikoMed will be attending BIO. Anders Kristensson, CEO and Adam Bruce, Founder and Executive Board Member will be attending the meeting with a focus on finding partners and collaborations for our two programs ILB and IBsolvMIR. The BIO International Convention (BIO) attracts 16,000+ biotechnology and pharma leaders who come together for one week of…
Read More
May 4, 2019
Kallelse till årsstämma i TIKOMED AB Aktieägarna i TIKOMED AB ( 556622-8960) kallas härmed till årsstämma den 17 juni 2019, kl. 11.00 på Restaurang Bryggan, Småbåtshamnen 16B i Höganäs. Aktieägare som önskar delta i bolagsstämman ombeds att senast kl.12.00 den 7 juni 2019 anmäla sin avsikt att delta till bolaget. Tillgängliga handlingar Årsredovisning och revisionsberättelse…
Read More
April 23, 2019
Cell and Gene on the Med
TikoMed will be pariticpating at The Cell & Gene Meeting on the Mediterranean, a two-day conference bringing together the entire cell and gene therapy community from Europe and beyond. Covering a wide range of commercialization topics from market access and regulatory issues to manufacturing and financing the sector, this program will feature expert-led panels, extensive…
Read More
January 5, 2019
The investor and networking conference for public and private biotech companies to meet with and present to investors and pharmaceutical executives during the course of the healthcare industry’s most important week of the year.…
Read More